Marker Therapeutics, Inc.
MRKR evidence brief
What we can confirm
- Market Cap:
- $19.2M
What it means
What to watch
Prepared research question
What matters most for MRKR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MRKR
Marker Therapeutics, Inc. (MRKR) is a clinical-stage immuno-oncology company developing multi-antigen recognizing (MAR)-T cell therapies for hematologic malignancies and solid tumors, with lead program MT-601 in Phase 2 for lymphoma.
Key risk: Cash runway limited
Market Cap
$19.2M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 4 clinical trials for Marker Therapeutics, Inc..
Marker Therapeutics, Inc. (MRKR) is a clinical-stage immuno-oncology company developing multi-antigen recognizing (MAR)-T cell therapies for hematologic malignancies and solid tumors, with lead program MT-601 in Phase 2 for lymphoma.
- Lead program MT-601 (neldaleucel) is a multi-antigen recognizing T cell therapy targeting five TAAs, currently in Phase 2 for non-Hodgkin lymphoma [pipeline].
- Cash & equivalents of $11.3M as of 2026-06-30, with net income of -$1.8M for the same period [sec].
- Company has received multiple non-dilutive grants totaling $2.0M each from CPRIT, FDA Orphan Products, and NIH SBIR for MT-401 and MT-601 programs [sec_mda · as of 2026-08-14].
- Phase 1 APOLLO study of MT-601 in 24 B-cell lymphoma patients who relapsed after CAR-T therapy reported clinical data with a cutoff of June 2025 [sec_mda · as of 2026-08-14].
- Cash runway estimated into Q2 2027 based on current cash and historical operating losses, assuming no additional grant funds [sec_mda · as of 2026-08-14].
What works
- Multiple non-dilutive government grants (CPRIT, FDA, NIH SBIR) support clinical development of MT-401 and MT-601, reducing near-term capital needs [sec_mda · as of 2026-08-14].
- Manufacturing partnership with Kincellis Advanced Therapies (formed from Cellipont and Kincell Bio) provides expanded infrastructure and expertise for MT-601 [news · published 2026-09-22].
- Lead program MT-601 targets patients who have relapsed after anti-CD19 CAR-T therapy, addressing a defined unmet need in lymphoma [sec_mda · as of 2026-08-14].
What to weigh
- No revenues from commercial product sales to date; company is entirely dependent on grant funding and capital raises [sec_mda · as of 2026-08-14].
- Net cash used in operating activities was $6.7M for the six months ended June 30, 2026, with cash runway only into Q2 2027 without additional funds [sec_mda · as of 2026-08-14].
- All programs are in early clinical stages (Phase 1/2), with no approved products and significant development risk [pipeline].
- Shareholders' equity of $12.2M as of 2026-06-30 is modest relative to ongoing cash burn [sec].
From the filings
Quoted directly from source documents.
Lead program MT-601 is in Phase 2 for non-Hodgkin lymphoma
“Pipeline Candidate: mt-601 Indication: Non-Hodgkin Lymphoma, Adult Phase: Phase 2”
Pipeline
Cash runway into Q2 2027
“we anticipate that we will be able to fund our operating expenses and capital expenditure requirements into the second quarter of 2027, assuming no additional grant funds are received”
SEC MD&A · August 14, 2026
Phase 1 APOLLO study data on 24 B-cell lymphoma patients
“clinical data was available for a total of 24 B-cell lymphoma patients from 7 clinical”
SEC MD&A · August 14, 2026
Catalyst timeline
- 2020-10-14 · Phase 2 Start: A Phase 2 Study of Donor-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-401) Administered to Patients With Acute Myeloid Leukemia (AML) Following Hematopoietic Stem Cell Transplantation — This Phase 2 study for MT-401 in AML post-transplant is ongoing; watch for enrollment updates or data readouts.
- 2023-01-02 · Phase 1 Start: A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen-Specific T Cells (MT-601) Administered to Patients With Relapsed or Refractory Non-Hodgkin and Hodgkin Lymphoma (APOLLO) — Phase 1 APOLLO study for MT-601 in lymphoma; clinical data from 24 patients reported as of June 2025.
- 2025-06-16 · Phase 1 Start: A Phase 1 Study of Allogenic Off-the-Shelf Multi-Tumor-Associated Antigen-Specific T Cell Products (MT-401-OTS) Administered to Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndromes (RAPID) — Phase 1 RAPID study for off-the-shelf MT-401-OTS in AML/MDS; early safety and efficacy data are key.
- 2026-07-16 · Phase 1 Start: A Phase 1 Study With — Another Phase 1 study initiated; details truncated in source, watch for full disclosure.
Risks & what to watch (3)›
Key risks
- Cash runway limited — Cash runway only into Q2 2027 without additional grants or capital raises; net cash used in operations was $6.7M in H1 2026 [sec_mda · as of 2026-08-14].
- No commercial revenue — Company has no approved products and no revenue from commercial sales; entirely dependent on grants and equity financing [sec_mda · as of 2026-08-14].
- Early-stage pipeline — All candidates are in Phase 1 or 2; no guarantee of regulatory approval or commercial success [pipeline].
What to watch
- Initiation of Phase 2 for MT-601 in non-Hodgkin lymphoma and any further clinical data updates [pipeline].
- Receipt of additional grant funds or capital raises to extend cash runway beyond Q2 2027 [sec_mda · as of 2026-08-14].
- Progress of MT-401-OTS Phase 1 RAPID study in AML/MDS [catalyst].
- Manufacturing scale-up and partnership outcomes with Kincellis Advanced Therapies [news · published 2026-09-22].
Sources: Catalysts · News · Pipeline · SEC MD&A · Generated October 4, 2026 · How we verify sources →
Run Marker Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Marker Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
36
Total value held
$5.1M
| Holder | Shares | Value |
|---|---|---|
| nea management company, llc | 1,625,678 | $2.1M |
| blue owl capital holdings lp | 554,250 | $721K |
| vanguard capital management llc | 389,319 | $506K |
| aisling capital management lp | 325,370 | $423K |
| renaissance technologies llc | 175,294 | $228K |
| geode capital management, llc | 160,910 | $209K |
| osaic holdings, inc. | 93,121 | $121K |
| vanguard fiduciary trust co | 87,269 | $113K |
| lpl financial llc | 83,047 | $108K |
| xtx topco ltd | 63,567 | $83K |
Showing top 10 of 36 institutional holders of Marker Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 28, 2026- % of float
- 1.4%
- Days to cover
- 1.2
- Shares short
- 190,658
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MRKR short interestGovernance
Frequently asked questions
What is the AI investment thesis for Marker Therapeutics, Inc.?
Marker Therapeutics, Inc. (MRKR) is a clinical-stage immuno-oncology company developing multi-antigen recognizing (MAR)-T cell therapies for hematologic malignancies and solid tumors, with lead program MT-601 in Phase 2 for lymphoma.
Who is the CEO of Marker Therapeutics, Inc.?
Dr. Juan F. Vera M.D. is the chief executive officer of Marker Therapeutics, Inc. (MRKR).
Where is Marker Therapeutics, Inc. headquartered?
Marker Therapeutics, Inc. (MRKR) is headquartered in Houston, TX, United States.
What therapeutic areas does Marker Therapeutics, Inc. focus on?
Marker Therapeutics, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.